Tekla Capital Management LLC historic quarter change: USA Stocks, Reduced
In share positions in stocks (listed in the US), over 13 quarters from 2013-06-30 to 2016-09-30, Tekla Capital Management LLC opened 83 positions, added to 135, reduced 85 and sold out of 38.
- Q3 2016: Stock HCA; Country of operation United States; Class Common; Shares before 334,998.
- Q3 2016: Stock PFE; Country of operation United States; Class Common; Shares before 1,483,291.
- Q3 2016: Stock ACAD; Country of operation United States; Class Common; Shares before 363,585.
- Q3 2016: Stock ILMN; Country of operation United States; Class Common; Shares before 371,364.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1300336), 13 quarters: Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-09); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-09); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-13); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-12); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-06); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-01-30); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-05); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-13); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-01-28); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-10-30). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2004-06-30.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q3 2016 | HCA
HCA Holdings, Inc. | United States | Common | 334,998 | 95,684 | -239,314 | $25,798,000 | $7,237,000 | -$18,561,000 | 2016-11-14 |
|---|
| Q3 2016 | PFE
Pfizer Inc. | United States | Common | 1,483,291 | 1,146,689 | -336,602 | $52,227,000 | $38,838,000 | -$13,389,000 | 2016-11-14 |
|---|
| Q3 2016 | ACAD
ACADIA Pharmaceuticals Inc. | United States | Common | 363,585 | 111,800 | -251,785 | $11,802,000 | $3,556,000 | -$8,246,000 | 2016-11-14 |
|---|
| Q3 2016 | ILMN
Illumina, Inc. | United States | Common | 371,364 | 246,560 | -124,804 | $52,132,000 | $44,790,000 | -$7,342,000 | 2016-11-14 |
|---|
| Q3 2016 | MDT
Medtronic plc | Ireland | Shares | 683,704 | 623,030 | -60,674 | $59,325,000 | $53,830,000 | -$5,495,000 | 2016-11-14 |
|---|
| Q3 2016 | EXEL
Exelixis, Inc. | United States | Common | 1,405,420 | 551,647 | -853,773 | $10,976,000 | $7,056,000 | -$3,920,000 | 2016-11-14 |
|---|
| Q3 2016 | MOH
Molina Healthcare, Inc. | United States | Common | 537,901 | 402,541 | -135,360 | $26,841,000 | $23,476,000 | -$3,365,000 | 2016-11-14 |
|---|
| Q3 2016 | AMGN
Amgen Inc. | United States | Common | 331,740 | 321,640 | -10,100 | $50,474,000 | $53,653,000 | +$3,179,000 | 2016-11-14 |
|---|
| Q3 2016 | COR
AmerisourceBergen Corporation | United States | Common | 376,500 | 330,687 | -45,813 | $29,864,000 | $26,713,000 | -$3,151,000 | 2016-11-14 |
|---|
| Q3 2016 | ARDX
Ardelyx, Inc. | United States | Common | 1,389,370 | 707,636 | -681,734 | $12,129,000 | $9,157,000 | -$2,972,000 | 2016-11-14 |
|---|
| Q3 2016 | ALKS
Alkermes plc | | Shares | 693,844 | 581,944 | -111,900 | $29,988,000 | $27,369,000 | -$2,619,000 | 2016-11-14 |
|---|
| Q3 2016 | NBIX
Neurocrine Biosciences, Inc. | United States | Common | 767,022 | 656,622 | -110,400 | $34,861,000 | $33,251,000 | -$1,610,000 | 2016-11-14 |
|---|
| Q3 2016 | MPT
Medical Properties Trust, Inc. | United States | Common | 920,393 | 839,217 | -81,176 | $13,999,000 | $12,395,000 | -$1,604,000 | 2016-11-14 |
|---|
| Q3 2016 | NTLA
Intellia Therapeutics, Inc. | United States | Common | 86,842 | 71,842 | -15,000 | $1,854,000 | $1,223,000 | -$631,000 | 2016-11-14 |
|---|
| Q3 2016 | A
Agilent Technologies, Inc. | United States | Common | 495,450 | 459,950 | -35,500 | $21,978,000 | $21,659,000 | -$319,000 | 2016-11-14 |
|---|
| Q2 2016 | VTR
Ventas, Inc. | United States | Common | 369,266 | 152,491 | -216,775 | $23,249,000 | $11,104,000 | -$12,145,000 | 2016-08-12 |
|---|
| Q2 2016 | MCK
McKesson Corporation | United States | Common | 82,862 | 15,000 | -67,862 | $13,030,000 | $2,800,000 | -$10,230,000 | 2016-08-12 |
|---|
| Q2 2016 | ACAD
ACADIA Pharmaceuticals Inc. | United States | Common | 715,299 | 363,585 | -351,714 | $20,000,000 | $11,802,000 | -$8,198,000 | 2016-08-12 |
|---|
| Q2 2016 | A
Agilent Technologies, Inc. | United States | Common | 713,850 | 495,450 | -218,400 | $28,447,000 | $21,978,000 | -$6,469,000 | 2016-08-12 |
|---|
| Q2 2016 | MPT
Medical Properties Trust, Inc. | United States | Common | 1,564,060 | 920,393 | -643,667 | $20,301,000 | $13,999,000 | -$6,302,000 | 2016-08-12 |
|---|
| Q2 2016 | UNH
UnitedHealth Group, Inc. | United States | Common | 409,100 | 331,100 | -78,000 | $52,733,000 | $46,751,000 | -$5,982,000 | 2016-08-12 |
|---|
| Q2 2016 | LTC
LTC Properties Inc. | United States | Common | 236,618 | 106,212 | -130,406 | $10,705,000 | $5,494,000 | -$5,211,000 | 2016-08-12 |
|---|
| Q2 2016 | ICLR
ICON plc | | Shares | 114,900 | 72,000 | -42,900 | $8,629,000 | $5,041,000 | -$3,588,000 | 2016-08-12 |
|---|
| Q2 2016 | PFE
Pfizer Inc. | United States | Common | 1,812,011 | 1,483,291 | -328,720 | $53,708,000 | $52,227,000 | -$1,481,000 | 2016-08-12 |
|---|
| Q2 2016 | JAZZ
Jazz Pharmaceuticals plc | | Shares | 179,091 | 156,451 | -22,640 | $23,380,000 | $22,108,000 | -$1,272,000 | 2016-08-12 |
|---|
| Q2 2016 | INCY
Incyte Corporation | United States | Common | 956,461 | 880,461 | -76,000 | $69,315,000 | $70,419,000 | +$1,104,000 | 2016-08-12 |
|---|
| Q2 2016 | JNJ
Johnson & Johnson | United States | Common | 375,088 | 337,312 | -37,776 | $40,585,000 | $40,916,000 | +$331,000 | 2016-08-12 |
|---|
| Q1 2016 | JNJ
Johnson & Johnson | United States | Common | 940,988 | 375,088 | -565,900 | $96,658,000 | $40,585,000 | -$56,073,000 | 2016-05-09 |
|---|
| Q1 2016 | ILMN
Illumina, Inc. | United States | Common | 434,341 | 348,864 | -85,477 | $83,370,000 | $56,554,000 | -$26,816,000 | 2016-05-09 |
|---|
| Q1 2016 | HCA
HCA Holdings, Inc. | United States | Common | 448,488 | 334,998 | -113,490 | $30,331,000 | $26,147,000 | -$4,184,000 | 2016-05-09 |
|---|
| Q1 2016 | A
Agilent Technologies, Inc. | United States | Common | 728,650 | 713,850 | -14,800 | $30,465,000 | $28,447,000 | -$2,018,000 | 2016-05-09 |
|---|
| Q1 2016 | DVAX
Dynavax Technologies Corporation | United States | Common | 275,000 | 240,950 | -34,050 | $6,644,000 | $4,636,000 | -$2,008,000 | 2016-05-09 |
|---|
| Q4 2015 | MDRX
Allscripts Healthcare Solutions, Inc. | United States | Common | 1,778,200 | 173,600 | -1,604,600 | $22,050,000 | $2,670,000 | -$19,380,000 | 2016-02-09 |
|---|
| Q4 2015 | BMY
Bristol-Myers Squibb Co. | United States | Common | 535,240 | 202,600 | -332,640 | $31,686,000 | $13,937,000 | -$17,749,000 | 2016-02-09 |
|---|
| Q4 2015 | ALNY
Alnylam Pharmaceuticals, Inc. | United States | Common | 281,474 | 137,495 | -143,979 | $22,619,000 | $12,944,000 | -$9,675,000 | 2016-02-09 |
|---|
| Q4 2015 | UTHR
United Therapeutics Corporation | United States | Common | 182,600 | 93,100 | -89,500 | $23,964,000 | $14,580,000 | -$9,384,000 | 2016-02-09 |
|---|
| Q4 2015 | ABBV
AbbVie Inc. | United States | Common | 164,156 | 156 | -164,000 | $8,932,000 | $9,000 | -$8,923,000 | 2016-02-09 |
|---|
| Q4 2015 | NBIX
Neurocrine Biosciences, Inc. | United States | Common | 375,860 | 311,460 | -64,400 | $14,955,000 | $17,619,000 | +$2,664,000 | 2016-02-09 |
|---|
| Q4 2015 | BIIB
Biogen Inc. | United States | Common | 467,183 | 450,533 | -16,650 | $136,329,000 | $138,021,000 | +$1,692,000 | 2016-02-09 |
|---|
| Q4 2015 | LXRX
Lexicon Pharmaceuticals, Inc. | United States | Common | 353,900 | 197,641 | -156,259 | $3,801,000 | $2,631,000 | -$1,170,000 | 2016-02-09 |
|---|
| Q4 2015 | ARDX
Ardelyx, Inc. | United States | Common | 640,270 | 639,370 | -900 | $11,064,000 | $11,585,000 | +$521,000 | 2016-02-09 |
|---|
| Q3 2015 | AMGN
Amgen Inc. | United States | Common | 497,280 | 321,640 | -175,640 | $76,342,000 | $44,489,000 | -$31,853,000 | 2015-11-13 |
|---|
| Q3 2015 | REGN
Regeneron Pharmaceuticals, Inc. | United States | Common | 187,166 | 154,266 | -32,900 | $95,479,000 | $71,755,000 | -$23,724,000 | 2015-11-13 |
|---|
| Q3 2015 | ESPR
Esperion Therapeutics, Inc. | United States | Common | 148,000 | 102,800 | -45,200 | $12,100,000 | $2,425,000 | -$9,675,000 | 2015-11-13 |
|---|
| Q3 2015 | HRTX
Heron Therapeutics, Inc. | United States | Common | 436,970 | 219,000 | -217,970 | $13,616,000 | $5,344,000 | -$8,272,000 | 2015-11-13 |
|---|
| Q2 2015 | ABBV
AbbVie Inc. | United States | Common | 1,110,614 | 156 | -1,110,458 | $65,015,000 | $10,000 | -$65,005,000 | 2015-08-12 |
|---|
| Q2 2015 | GILD
Gilead Sciences, Inc. | United States | Common | 2,279,731 | 2,079,731 | -200,000 | $223,710,000 | $243,495,000 | +$19,785,000 | 2015-08-12 |
|---|
| Q2 2015 | TMO
Thermo Fisher Scientific Inc. | United States | Common | 141,695 | 86,395 | -55,300 | $19,035,000 | $11,211,000 | -$7,824,000 | 2015-08-12 |
|---|
| Q2 2015 | INCY
Incyte Corporation | United States | Common | 936,461 | 880,461 | -56,000 | $85,836,000 | $91,753,000 | +$5,917,000 | 2015-08-12 |
|---|
| Q2 2015 | NBIX
Neurocrine Biosciences, Inc. | United States | Common | 501,150 | 375,860 | -125,290 | $19,901,000 | $17,951,000 | -$1,950,000 | 2015-08-12 |
|---|
| Q2 2015 | ALNY
Alnylam Pharmaceuticals, Inc. | United States | Common | 130,195 | 103,495 | -26,700 | $13,595,000 | $12,406,000 | -$1,189,000 | 2015-08-12 |
|---|
| Q2 2015 | HRTX
Heron Therapeutics, Inc. | United States | Common | 873,940 | 436,970 | -436,970 | $12,716,000 | $13,616,000 | +$900,000 | 2015-08-12 |
|---|
| Q2 2015 | JAZZ
Jazz Pharmaceuticals plc | | Shares | 120,741 | 120,357 | -384 | $20,863,000 | $21,191,000 | +$328,000 | 2015-08-12 |
|---|
| Q1 2015 | VRTX
Vertex Pharmaceuticals, Inc. | United States | Common | 701,944 | 464,244 | -237,700 | $83,391,000 | $54,767,000 | -$28,624,000 | 2015-05-06 |
|---|
| Q1 2015 | BMRN
BioMarin Pharmaceutical Inc. | United States | Common | 570,027 | 534,977 | -35,050 | $51,530,000 | $66,669,000 | +$15,139,000 | 2015-05-06 |
|---|
| Q1 2015 | JAZZ
Jazz Pharmaceuticals plc | | Shares | 201,341 | 120,741 | -80,600 | $32,966,000 | $20,863,000 | -$12,103,000 | 2015-05-06 |
|---|
| Q1 2015 | AMGN
Amgen, Inc. | United States | Common | 380,279 | 351,779 | -28,500 | $60,575,000 | $56,232,000 | -$4,343,000 | 2015-05-06 |
|---|
| Q1 2015 | REGN
Regeneron Pharmaceuticals, Inc. | United States | Common | 198,366 | 187,166 | -11,200 | $81,380,000 | $84,502,000 | +$3,122,000 | 2015-05-06 |
|---|
| Q1 2015 | NBIX
Neurocrine Biosciences, Inc. | United States | Common | 1,000,350 | 501,150 | -499,200 | $22,348,000 | $19,901,000 | -$2,447,000 | 2015-05-06 |
|---|
| Q1 2015 | SRPT
Sarepta Therapeutics, Inc. | United States | Common | 345,400 | 230,300 | -115,100 | $4,998,000 | $3,058,000 | -$1,940,000 | 2015-05-06 |
|---|
| Q1 2015 | MYGN
Myriad Genetics, Inc. | United States | Common | 112,200 | 74,800 | -37,400 | $3,822,000 | $2,648,000 | -$1,174,000 | 2015-05-06 |
|---|
| Q1 2015 | SRNE
Sorrento Therapeutics, Inc. | United States | Common | 213,896 | 142,597 | -71,299 | $2,154,000 | $1,648,000 | -$506,000 | 2015-05-06 |
|---|
| Q4 2014 | GILD
Gilead Sciences, Inc. | United States | Common | 2,490,531 | 2,080,731 | -409,800 | $265,117,000 | $196,130,000 | -$68,987,000 | 2015-01-30 |
|---|
| Q4 2014 | ILMN
Illumina, Inc. | United States | Common | 229,341 | 103,841 | -125,500 | $37,594,000 | $19,167,000 | -$18,427,000 | 2015-01-30 |
|---|
| Q4 2014 | TMO
Thermo Fisher Scientific Inc. | United States | Common | 266,875 | 120,995 | -145,880 | $32,479,000 | $15,159,000 | -$17,320,000 | 2015-01-30 |
|---|
| Q4 2014 | INCY
Incyte Corporation | United States | Common | 1,141,961 | 936,461 | -205,500 | $56,013,000 | $68,465,000 | +$12,452,000 | 2015-01-30 |
|---|
| Q4 2014 | AMGN
Amgen Inc. | United States | Common | 510,042 | 380,279 | -129,763 | $71,640,000 | $60,575,000 | -$11,065,000 | 2015-01-30 |
|---|
| Q4 2014 | PFE
Pfizer, Inc. | United States | Common | 1,902,241 | 1,638,241 | -264,000 | $56,249,000 | $51,031,000 | -$5,218,000 | 2015-01-30 |
|---|
| Q4 2014 | NBIX
Neurocrine Biosciences, Inc. | United States | Common | 1,281,950 | 1,000,350 | -281,600 | $20,088,000 | $22,348,000 | +$2,260,000 | 2015-01-30 |
|---|
| Q4 2014 | INFIQ
Infinity Pharmaceuticals, Inc. | United States | Common | 680,746 | 438,623 | -242,123 | $9,136,000 | $7,408,000 | -$1,728,000 | 2015-01-30 |
|---|
| Q4 2014 | BMRN
BioMarin Pharmaceutical Inc. | United States | Common | 710,527 | 570,027 | -140,500 | $51,272,000 | $51,530,000 | +$258,000 | 2015-01-30 |
|---|
| Q4 2014 | MGNX
Macrogenics, Inc. | United States | Common | 31,857 | 12,743 | -19,114 | $666,000 | $447,000 | -$219,000 | 2015-01-30 |
|---|
| Q3 2014 | REGN
Regeneron Pharmaceuticals, Inc. | United States | Common | 193,466 | 187,166 | -6,300 | $54,648,000 | $67,477,000 | +$12,829,000 | 2014-11-14 |
|---|
| Q2 2014 | PRGO
Perrigo Company plc | Ireland | Shares | 167,874 | 62,952 | -104,922 | $25,963,000 | $9,176,000 | -$16,787,000 | 2014-08-05 |
|---|
| Q2 2014 | REGN
Regeneron Pharmaceuticals, Inc. | United States | Common | 211,166 | 193,466 | -17,700 | $63,409,000 | $54,648,000 | -$8,761,000 | 2014-08-05 |
|---|
| Q1 2014 | REGN
Regeneron Pharmaceuticals, Inc. | United States | Common | 260,699 | 211,166 | -49,533 | $71,755,000 | $63,409,000 | -$8,346,000 | 2014-05-13 |
|---|
| Q1 2014 | BIIB
Biogen Idec, Inc. | United States | Common | 191,983 | 173,983 | -18,000 | $53,707,000 | $53,216,000 | -$491,000 | 2014-05-13 |
|---|
| Q1 2014 | INCY
Incyte Corporation | United States | Common | 588,300 | 558,080 | -30,220 | $29,786,000 | $29,868,000 | +$82,000 | 2014-05-13 |
|---|
| Q4 2013 | PBYI
Puma Biotechnology, Inc. | United States | Common | 458,816 | 185,820 | -272,996 | $24,620,000 | $19,238,000 | -$5,382,000 | 2014-01-28 |
|---|
| Q4 2013 | NBIX
Neurocrine Biosciences, Inc. | United States | Common | 570,387 | 427,790 | -142,597 | $6,457,000 | $3,996,000 | -$2,461,000 | 2014-01-28 |
|---|
| Q4 2013 | HOLX
Hologic, Inc. | United States | Common | 592,915 | 444,687 | -148,228 | $12,244,000 | $9,939,000 | -$2,305,000 | 2014-01-28 |
|---|
| Q3 2013 | REGN
Regeneron Pharmaceuticals, Inc. | United States | Common | 279,759 | 260,699 | -19,060 | $62,912,000 | $81,565,000 | +$18,653,000 | 2013-10-30 |
|---|
| Q3 2013 | PBYI
Puma Biotechnology, Inc. | United States | Common | 711,800 | 458,816 | -252,984 | $31,583,000 | $24,620,000 | -$6,963,000 | 2013-10-30 |
|---|
| Q3 2013 | NBIX
Neurocrine Biosciences, Inc. | United States | Common | 707,990 | 570,387 | -137,603 | $9,473,000 | $6,457,000 | -$3,016,000 | 2013-10-30 |
|---|
| Q3 2013 | CVS
CVS Caremark Corporation | United States | Common | 71,591 | 53,694 | -17,897 | $4,094,000 | $3,047,000 | -$1,047,000 | 2013-10-30 |
|---|
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|
| Not available yet |